HPV Vaccine Before 14: Zero Cervical Cancer Cases in 450K Women Study
- WHO: Optimizing Vaccination Can Reduce the Use of 2.5 Billion Doses of Antibiotics Each Year
- $3 Million Lentiviral Gene Therapy Linked to Cases of Blood Cancer
- Mycoplasma Pneumonia Outbreak in Japan: Still Travel to Japan?
- Is Zero-Calorie Sweetener Harmful?
- Can Collagen Effectively Fight Wrinkles and Aging?
- Hurricane Milton Brings Severe Shortage of Intravenous Solutions in US
HPV Vaccine Before 14: Zero Cervical Cancer Cases in 450K Women Study
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
HPV Vaccine Before 14: Zero Cervical Cancer Cases in 450K Women Study
Data from a Study of 450,000 Women: No Cases of Invasive Cervical Cancer in Those Vaccinated Against HPV Before the Age of 14.
On January 22, a study titled “Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation” was published in JNCI.
The research included approximately 450,000 women born between January 1, 1988, and June 5, 1996. Among them, about 40,000 women received the HPV vaccine between the ages of 12 and 13, 124,000 women received the vaccine at 14 years old or later, and 300,000 women did not receive the HPV vaccine.
The study’s findings revealed that among women vaccinated with the HPV vaccine between the ages of 12 and 13, regardless of the number of doses, no cases of invasive cervical cancer were recorded. In comparison to women who did not receive the HPV vaccine, those who received the vaccine between the ages of 14 and 22 and completed the full course of the bivalent vaccine had a significantly lower incidence of cervical cancer.
The unadjusted incidence rates for women from the most impoverished areas were significantly higher than those from the wealthiest regions. However, women from the most impoverished areas experienced a significant reduction in incidence rates after receiving the full three doses of the vaccine.
The study concludes that the bivalent HPV vaccine can prevent the development of invasive cervical cancer. Even with just one or two doses administered at the age of 12-13, beneficial effects were observed. In older age groups, the administration of all three doses is necessary to achieve statistically significant vaccine effectiveness. (Source: JNCI)
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
